Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars
Pearce IP BioBlast®: w/e 08 October 2021

Pearce IP BioBlast®: w/e 08 October 2021

27 Sep 21 | CA | Apobiologix announced that Health Canada has approved Bambevi® (biosimilar bevacizumab) in combination with chemotherapy to treat specific types of colorectal, lung, brain and ovarian cancer. 02 Oct 21 | A new study published in Cancer Communications...
Pearce IP BioBlast®: w/e 08 October 2021

Pearce IP BioBlast®: w/e 01 October 2021

27 Sep 21 | Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD $375 million with a further USD $50 million in contingent consideration payable upon the achievement of certain commercial milestones. 27 Sep 21 | CN...
Pearce IP BioBlast®: w/e 08 October 2021

Pearce IP BioBlast®: w/e 24 September 2021

18 Sep 21 | Merck announced that the first results from Ph III trials of Keytruda® (pembrolizumab) showed a statistically significant and clinically meaningful improvement in recurrence-free survival compared to placebo in patients with resected high-risk stage II...
Pearce IP BioBlast®: w/e 08 October 2021

Pearce IP BioBlast®: w/e 17 September 2021

13 Sep 21 | Samsung Bioepis reported on a five-year follow-up study comparing ONTRUZANT® (trastuzumab biosimilar) with reference trastuzumab in early or locally advanced HER2 positive breast cancer. Samsung Bioepis reported that five year survival rates were 93.1% in...
Pearce IP BioBlast®: w/e 08 October 2021

Pearce IP BioBlast®: w/e 10 September 2021

02 Sep 21 | US | Amgen and Hospira appear ready to settle the ongoing dispute relating to Neupogen® (filgrastim). The matter was due to go to a jury trial on 20 September 2021. 06 Sep 21 | IN | Hetero announced that it has received emergency use approval from India’s...